Sector News

Bayer, Sensyne to form new AI ‘LifeHub’

October 10, 2019
Life sciences

Sensyne has announced a new partnership – its second this week – with Bayer, in order to accelerate the development of new treatments using clinical artificial intelligence.

The company revealed that it will work in partnership with the German pharma giant on novel projects at the LifeHub UK, including its inaugural project – the development of AI-enabled radiology to enhance patient outcomes.

LifeHub UK, which launches today, forms part of a global network of Bayer innovation hubs, designed to accelerate and optimise disease detection and data-driven drug discovery by enabling Artificial Intelligence (AI)-enabled imaging solutions.

The companies have announced that the first LifeHub UK project will focus on the development of AI-enabled radiology solutions using Sensyne Health’s proprietary clinical AI technology platform to identify digital solutions for automated image evaluation.

The project will analyse research from three million anonymised, ethically sourced NHS patient records and imaging data provided through Sensyne Health’s partnerships with NHS trusts, developing digital solutions to help radiologists improve the quality of the diagnosis and increase efficiency for patients receiving the right treatment in a timely manner.

Kemal Malik, Bayer board member for innovation, said that the company is “delighted to launch LifeHub UK,” and that it firmly believes “artificial intelligence has transformative potential for healthcare, leading to enhancements in prediction, prevention and personalised treatments.

“LifeHub UK’s roadmap is a perfect fit to Bayer’s Open Innovation strategy, which is designed to leverage places, programmes and partnerships – such as strategic alliances and joint ventures – in the life sciences fields of pharmaceuticals and agriculture.”

Earlier this week Sensyne announced a formal research agreement with the UK Medicines and Healthcare Products Regulatory Agency (MHRA), to contribute to the development of methods to validate software algorithms used in digital health.

The company is also already part of a partnership with the University of Oxford’s Big Data Institute (BDI), using data science and clinical artificial intelligence (clinical AI) for the patient-centred management and treatment of chronic disease.

By Anna Smith

Source: Pharma Times

comments closed

Related News

September 19, 2021

From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year

Life sciences

This year has already witnessed a handful of memorable FDA approvals. But the race isn’t over yet. Looking to close out 2021 with FDA approvals stand four potential blockbusters from the likes of Argenx, UCB, Pfizer and Roche, according to Evaluate Pharma. Those meds combined are worth roughly $7.1 billion in sales cumulatively by 2026, according to Evaluate’s estimates.

September 19, 2021

Horizon partners with MIT for crowdsourced rare disease solutions, narrows to 5 finalists

Life sciences

Getting started is often the most difficult part—and that’s especially true in rare diseases and diagnoses. Patients and families often spend many years searching for their diagnosis starting point. For Horizon Therapeutics’ first innovation challenge, it took that struggle to heart and asked for technology-based rare disease solutions that result in faster or more accurate diagnoses.

September 19, 2021

Research identifies possible link between antibiotic use and breast cancer growth

Life sciences

Researchers from the Quadram Institute and the University of East Anglia (UEA) discovered that treating mice with broad-spectrum antibiotics increased the rate at which their breast cancer tumours grew.

Send this to a friend